Belantamab

Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239) . After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma[1][2].

Product Specifications

CAS Number

[2061894-48-0]

Product Name Alternative

GSK2857914

UNSPSC

12352203

Target

ADC Antibody; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/belantamab.html

Purity

99.90

Solubility

H2O

Smiles

[Belantamab]

Molecular Weight

(146.06 kDa)

References & Citations

[1]Ivo Demel, et al. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. Br J Haematol. 2021 May;193 (4) :705-722.|[2]Montes de Oca R, et al. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo. Mol Cancer Ther. 2021 Oct;20 (10) :1941-1955.